Vericel VCEL
NASDAQ VCEL
$40.19 -0.28 (-0.69%)
As of: Sep 4, 2026 · 3:59 PM EDT

Vericel (VCEL) Cash from Financing Activities (2010 - 2026)

Vericel (VCEL) posted Cash from Financing Activities of $2.7 million for Q2 2026, up 190.37% sequentially from -$3.0 million in Q1 2026, and up 64.05% YoY from $1.6 million in Q2 2025.

Analysis

Vericel (VCEL) Cash from Financing Activities (2010 - 2026) Analysis & Trends

Vericel has reported Cash from Financing Activities for 17 years, with the latest figure at $2.7 million in Q2 2026.

  • Quarterly Cash from Financing Activities rose 64.05% year-over-year to $2.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.9 million (down 88.87% YoY) and the FY2025 annual result came in at $7.1 million, down 62.89% from the prior year.
  • Cash from Financing Activities improved to $2.7 million in Q2 2026 per VCEL's latest filing, from -$3.0 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $7.1 million in Q4 2024 and troughed at -$3.0 million in Q1 2026.
  • A 5-year average of $1.7 million and a median of $1.2 million in 2023 frame the typical range for Cash from Financing Activities.
  • The sharpest annual moves came in 2024 and 2026: Cash from Financing Activities jumped 1886.92% in 2024, then sank 193.15% in 2026.
  • Over 5 years, Cash from Financing Activities stood at $605000.0 in 2022, then jumped by 116.03% to $1.3 million in 2023, then jumped by 443.84% to $7.1 million in 2024, then sank by 85.02% to $1.1 million in 2025, then surged by 152.77% to $2.7 million in 2026.
  • According to Business Quant data, Cash from Financing Activities over the past three periods registered $2.7 million, -$3.0 million, and $1.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -426.70 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -1.22 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 14.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 2.42 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -6.05 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 36.24 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -273.15 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 27.18 Mn
10 Vericel 2.05 Bn 1.89 Bn 56.40 Mn 2.69 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2.69 Mn
Mar 31, 2026 -2.98 Mn
Dec 31, 2025 1.07 Mn
Sep 30, 2025 1.17 Mn
Jun 30, 2025 1.64 Mn
Mar 31, 2025 3.20 Mn
Dec 31, 2024 7.11 Mn
Sep 30, 2024 5.52 Mn
Jun 30, 2024 4.30 Mn
Mar 31, 2024 2.13 Mn
Dec 31, 2023 1.31 Mn
Sep 30, 2023 1.01 Mn
Jun 30, 2023 1.20 Mn
Mar 31, 2023 107,000.00
Dec 31, 2022 605,000.00
Sep 30, 2022 -312,000.00
Jun 30, 2022 249,000.00
Mar 31, 2022 503,000.00
Dec 31, 2021 1.34 Mn
Sep 30, 2021 1.79 Mn